Atossa Therapeutics Reports Widened Losses, Significant Cash Burn, and Auditor's Going Concern Warning; Faces Critical Patent Challenges

summarizeSummary

Atossa Therapeutics' 2025 annual report highlights a going concern warning from its auditor, increased financial losses, and ongoing patent litigation against its core drug candidate, despite some positive clinical and regulatory developments.

check_boxKey Events

• Auditor Issues Going Concern Warning

  The company's independent registered public accounting firm has expressed 'substantial doubt' about Atossa Therapeutics' ability to continue as a going concern, citing recurring losses and negative operating cash flows.

• Significant Financial Deterioration in 2025

  Net loss widened to $34.8 million in 2025 from $25.5 million in 2024. Cash used in operating activities increased to $29.8 million in 2025 from $21.0 million in 2024, with cash and cash equivalents at $41.3 million as of December 31, 2025.

• Critical Patent Litigation Ongoing

  Intas Pharmaceuticals Ltd. filed two petitions with the USPTO's Patent Trial and Appeal Board (PTAB) on April 3, 2025, seeking to invalidate two patents related to the company's lead drug candidate, (Z)-endoxifen. The PTAB granted institution of both proceedings on November 3, 2025, with final decisions expected by November 3, 2026.

• New $50 Million At-The-Market (ATM) Offering Initiated

  On February 20, 2026, the company entered into a new ATM Offering Agreement to sell up to $50.0 million of common stock, replacing a prior $100.0 million facility that was terminated without any sales.

auto_awesomeAnalysis

Atossa Therapeutics' annual report reveals a dire financial situation, with auditors explicitly raising 'substantial doubt' about the company's ability to continue as a going concern. This warning is underpinned by a significant increase in net losses and cash burn from operations in 2025. The company's cash reserves are projected to last only 12 months, necessitating further capital raises. Compounding these financial challenges, the company is actively defending against two patent invalidation petitions from Intas Pharmaceuticals, which directly threaten the intellectual property of its lead drug candidate, (Z)-endoxifen. While recent FDA designations for (Z)-endoxifen in Duchenne Muscular Dystrophy offer long-term potential, the immediate financial instability and patent risks present critical headwinds for investors.